Pomerantz Law Firm Launches Investigation for Immutep Limited Investors Following Serious Allegations

Pomerantz Law Firm Investigates Immutep Limited

Pomerantz LLP, a well-established law firm known for its expertise in corporate, securities, and antitrust class litigation, has initiated an investigation for investors of Immutep Limited (NASDAQ: IMMP). This move comes after the company recently faced a significant drop in its American Depositary Receipt (ADR) price following alarming announcements regarding one of its clinical trials.

On March 13, 2026, Immutep issued a press release indicating that the Independent Data Monitoring Committee (IDMC) had recommended the discontinuation of the TACTI-004 Phase III study. This study was evaluating the efficacy of eftilagimod alfa ('efti') in patients with non-small cell lung cancer. The press release stated that, based on the committee's review of the currently available safety and efficacy data, the trial was deemed futile. Subsequently, this recommendation prompted an immediate halt to enrollment in the study and initiated the process for an orderly wind down, including necessary patient follow-ups and closure at testing sites, in line with regulatory and ethical obligations.

This troubling news sent waves through the investment community. Following the announcement, Immutep's ADR price plummeted by an astonishing $2.27, marking an 82.44% decrease, which drove the closing price down to a mere $0.48 per ADR on the same day. This dramatic drop has raised serious questions about the company's business practices and whether there has been a breach of duty by some of Immutep's officers and/or directors.

Pomerantz LLP urges investors who have suffered losses as a result of this downturn to reach out for assistance. Danielle Peyton, a representative from the firm, is available at [email protected] or at 646-581-9980, ext. 7980 to provide more information on how to join the potential class action.

With over 85 years in the field, Pomerantz has a robust history of fighting for the rights of victims of securities fraud. The firm has successfully recovered substantial damages awards for class members in previous cases. Notably, it was founded by the late Abraham L. Pomerantz, a pioneering figure known as the dean of the class action bar who instrumentalized the concept of securities class actions. Today, the firm continues to maintain this esteemed reputation while seeking justice for investors.

The investigation into Immutep also prompts investors to consider the implications of the findings. If it is determined that the company indeed engaged in wrongful practices, it could lead to significant repercussions, not just financially for the company but also for those in leadership roles. Stakeholders will be keenly watching how this legal scrutiny unfolds in the coming weeks.

As always, it is vital for investors to stay informed and to know their rights. Joining a class action might not only help in recovering losses but also shed light on any potentially unethical practices by the company’s management. Interested investors should monitor the situation carefully and consult with legal professionals regarding the next steps.

Pomerantz LLP remains committed to ensuring that investors receive fair treatment and that any misconduct is appropriately addressed. Investors looking for up-to-the-minute updates are encouraged to visit Pomerantz’s official website, where ongoing information will be made available as this case develops.